Stability of the proteasome inhibitor bortezomib in cell based assays determined by ultra-high performance liquid chromatography coupled to tandem mass spectrometry-Reference-Cited by-同舟云学术

Stability of the proteasome inhibitor bortezomib in cell based assays determined by ultra-high performance liquid chromatography coupled to tandem mass spectrometry

Published:2014-06 Issue: Volume:1345 Page:128-138
ISSN:0021-9673
Container-title:Journal of Chromatography A
language:en
Short-container-title:Journal of Chromatography A

Author:

Clemens Jannick,Longo Magdalena,Seckinger Anja,Hose Dirk,Haefeli Walter Emil,Weiss Johanna,Burhenne Jürgen

Publisher

Elsevier BV

Subject

Organic Chemistry,General Medicine,Biochemistry,Analytical Chemistry

Reference40 articles.

1. Intracellular Drug Concentrations

2. OCT-1–mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib

3. Proteasome inhibition in cancer: Development of PS-341

4. Proteasome Inhibition As a Novel Therapeutic Target in Human Cancer

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bortezomib at therapeutic doses poorly passes the blood–brain barrier and does not impair cognition;Brain Communications;2020-01-01

2. Elucidating the beneficial effects of melphalan, adriamycin, and corticoids in combination with bortezomib against multiple myeloma in vitro;Naunyn-Schmiedeberg's Archives of Pharmacology;2018-12-15

3. Cellular effect and efficacy of carfilzomib depends on cellular net concentration gradient;Cancer Chemotherapy and Pharmacology;2017-05-12

4. Antineoplastic drugs and their analysis: a state of the art review;The Analyst;2017

5. Supercritical fluid (CO2) chromatography for quantitative determination of selected cancer therapeutic drugs in the prescence of potential impurities in injection formulations;Analytical Methods;2017